- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03005717
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Potential subjects will present and complete the Screening Visit. All qualifying subjects will be randomized to one of three treatment groups and treated with up to 30 subcutaneous injections of the assigned study drug into submental fat, once a week for 8 weeks. Upon completion of treatment visits, subject will return to the clinic for a follow-up visit and end of study visit, one and four weeks after the last treatment. The number and pattern of injections will be based on the area (cm x cm) of submental fat at baseline. At each visit the subjects will also undergo an examination of the treatment area, collection of vital signs and questioning about possible adverse events (AEs).
The study consists of 11 visits: a Screening Visit, eight Treatment Visits, a Follow up Visit and an End of Study Visit.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90210
- Clinical Testing of Beverly Hills
-
Manhattan Beach, California, United States, 90266
- Ablon Skin Institute and Research Center
-
-
Colorado
-
Greenwood Village, Colorado, United States, 80113
- AboutSkin Research
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- Skin Research Institute
-
-
Michigan
-
Warren, Michigan, United States, 48088
- Grekin Skin Institute
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Minnesota Clinical Study Center
-
-
Missouri
-
Washington, Missouri, United States, 63090
- Mercy Research
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Skin Specialists, PC
-
-
New York
-
New York, New York, United States, 10022
- Juva Skin & Laser Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Tennessee Clinical Research Center
-
-
Texas
-
Austin, Texas, United States, 78746
- Westlake Dermatology Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males or non-pregnant females;
- Capable of providing written, informed consent; and ,
- Have submental bulging that is evaluated by the Investigator as "Moderate" or "Large".
Exclusion Criteria:
- History of prior treatment to reduce submental bulging;
- History of derm fillers, chemical peels, or laser or radio frequency procedures in the neck/chin area within 12 months of screening;
- History of botulinum toxin in the neck/chin area within 6 months of screening;
- Any skin conditions (including, but not limited to: skin infections, psoriasis, eczema, keloids, tattoos or hypertrophic or tethered scars) or history of trauma in the treatment area that may affect study procedures;
- A score of 4 (Extreme Laxity) on the Skin Laxity Assessment Scale at Visit 1 (Screening);
- Any known hypersensitivity to the study drug and/or any of the components;
- Prior or current enrollment in any Lithera/Neothetics sponsored LIPO-102/LIPO-202 study;
- Concurrently enrolled in another investigational drug or device study or used any experimental or investigational drug or device within 30 days of screening;
- Female subject who is pregnant or lactating;
Any medical condition that in the opinion of the Investigator might complicate study procedures or assessments or jeopardize the subject's safety, including, but not limited to:
- any bleeding or connective tissue disorders;
- any clinically significant kidney or liver disease;
- any untreated thyroid disease;
- asthma, COPD, diabetes (Type I and II) or cardiovascular disease
- history of major surgery within 30 days prior to randomization, or planned surgery during the study period;
- Used drugs with anticoagulant activity (including aspirin) within 14 days prior to randomization, β adrenergic receptor agonists or blockers, strong CYP3A inhibitors, or nonpotassium sparing diuretics (e.g., loop or thiazide diuretics) within 28 days prior to randomization;
- Used tricyclic antidepressants or monoamine oxidase inhibitor medications within 14 days prior to randomization;
- Unlikely or unable to adhere to the study visit schedule or comply with protocol procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active High
Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
|
Other Names:
|
Experimental: Active Low
Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
|
Other Names:
|
Placebo Comparator: Placebo
Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
|
Lyophile manufactured to mimic LIPO-202 lyophile.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by number of subjects with adverse events.
Time Frame: 12 weeks (Baseline through 4 weeks post last dose)
|
12 weeks (Baseline through 4 weeks post last dose)
|
|
Safety as measured by the number of subjects with abnormal post baseline shifts in laboratory results.
Time Frame: 12 weeks (Baseline through 4 weeks post last dose)
|
12 weeks (Baseline through 4 weeks post last dose)
|
|
Change from baseline in the patient reported submental bulging scale.
Time Frame: 12 weeks (Baseline through 4 weeks post last dose)
|
The self-rating scale is 5-point scale that the subject evaluates their submental fat.
|
12 weeks (Baseline through 4 weeks post last dose)
|
Change from baseline in the clinician reported submental bulging scale
Time Frame: 12 weeks (Baseline through 4 weeks post last dose)
|
The clinician scale is 5-point rating scale in which the clinician evaluates the subject's submental fat.
|
12 weeks (Baseline through 4 weeks post last dose)
|
Change in submental fat thickness measured with calipers (mm).
Time Frame: 12 weeks (Baseline through 4 weeks post last dose)
|
12 weeks (Baseline through 4 weeks post last dose)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Daniel Piacquadio, MD, Consultant, Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Salmeterol Xinafoate
Other Study ID Numbers
- LIPO-202-CL-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Submental Fat
-
Raziel Therapeutics Ltd.Completed
-
10xBio, LLCCompleted
-
Daewoong Pharmaceutical Co. LTD.UnknownSubmental FatKorea, Republic of
-
Kythera BiopharmaceuticalsCompletedHealthy | Submental FatUnited States, Canada
-
Raziel Therapeutics Ltd.CompletedSubmental FatUnited States
-
Raziel Therapeutics Ltd.Completed
-
10xBio, LLCActive, not recruitingSubmental FatUnited States
-
Raziel Therapeutics Ltd.Completed
-
Raziel Therapeutics Ltd.CompletedSubmental FatUnited States
-
Medy-ToxCompletedSubmental FatKorea, Republic of
Clinical Trials on LIPO-202
-
Evofem Inc.Neothetics, IncTerminatedCentral Abdominal Bulging
-
Neothetics, IncUnknown
-
Neothetics, IncCompletedCentral Abdominal BulgingUnited States
-
Neothetics, IncCompletedCentral Abdominal BulgingUnited States
-
Evofem Inc.Neothetics, IncCompletedCentral Abdominal BulgingUnited States
-
Neothetics, IncCompleted
-
Neothetics, IncCompletedSubcutaneous Adipose Tissue ReductionUnited States
-
Neothetics, IncCompletedThyroid-Related Eye DiseaseAustralia, New Zealand
-
Neothetics, IncCompleted
-
Devalingam MahalingamGenSpera, Inc.No longer availableHepatocellular Carcinoma